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T-plastin (PLS3) is an actin-bundling protein normally expressed in epithelial cells but absent in cells of
hematopoietic origin. Aberrant PLS3 expression has been demonstrated in lymphocytes from Se´zary syndrome
(SS) patients and has been proposed as a biomarker for SS; however, the mechanism underlying dysregulation
of PLS3 has not been determined. In this study, PLS3 mRNA expression was demonstrated in 21/35 (60%) SS
patients and in 3/8 (38%) mycosis fungoides patients, all of whom had clonal blood involvement. No evidence
for PLS3 mutations within coding or promoter regions was found, but significant hypomethylation of CpG
dinucleotides 95–99 within the PLS3 CpG island was observed and this was restricted to the PLS3þ population.
A polyclonal antibody specific to PLS3 was raised to examine coexpression of PLS3 with a panel of T-cell
differentiation markers. All PLS3þ cells were CD3þCD4þ and CD26, suggesting that loss of CD26 is
consistently associated with gain of PLS3, whereas all other markers were distributed heterogeneously.
However, a patient-specific TCR copy number assay also demonstrated heterogeneity in PLS3 expression in
tumor cell populations. Importantly, our findings demonstrate PLS3 expression in the majority of SS patients
and provide insight into the molecular regulation of PLS3 expression in CTCL.
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INTRODUCTION
Primary cutaneous T-cell lymphoma (CTCL) is the second
most common form of extranodal non-Hodgkin’s lymphoma
with an incidence of 7.7 in 1,000,000 person-years (Bradford
et al., 2009). Mycosis fungoides (MF) is the most prevalent
form of CTCL, accounting for 54% of cases (Bradford et al.,
2009). In MF, the tumor cells are usually restricted to the skin
compartment, and prognosis is generally favorable with a
5-year overall survival of 78% (Agar et al., 2010). Se´zary
syndrome (SS) is a closely related but more aggressive
subtype in which a leukemic clone of T cells is present in
the peripheral blood. SS is associated with a poor prognosis
and a 5-year overall survival of only 26% (Agar et al., 2010).
Diagnosis of the various subtypes of CTCL is made using a
combination of clinical, histological, and immunophenotypic
features, because there is a lack of biomarkers unique to the
disease or its subtypes. In SS, a measure of circulating tumor
burden can be obtained by visual inspection of a blood smear
to quantify those cells with abnormal cerebriform nuclei.
However, Se´zary cells are morphologically heterogeneous
and can be difficult to distinguish from normal activated
T cells based on morphology alone.
Previous studies have suggested a characteristic immuno-
phenotype typical of SS, including loss of CD7 (Haynes et al.,
1981), loss of CD26 (Jones et al., 2001), and the presence of
CD158k (Bagot et al., 2001). Increasingly, these differentia-
tion markers are being used in research studies to enrich for
the tumor cells (Contassot et al., 2008; Yoon et al., 2008).
However, a study comparing the use of the different
phenotypic markers as diagnostic tools concluded that no
individual marker is present in all cases, and that a
combination of markers is required for flow cytometric
diagnosis (Klemke et al., 2008). In addition, tumor cells have
been identified in FACS-sorted CD7- and CD26-positive
subsets from SS patient samples using a clone-specific TCR
PCR (Steinhoff et al., 2009), suggesting that these markers
may not be appropriate for enrichment of the tumor cell
population.
T-plastin (PLS3) is an actin-bundling protein, the expres-
sion of which is restricted to epithelial cells with replicative
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potential (Lin et al., 1993). A closely related isoform, L-
plastin, is normally expressed only in hematopoietic cells, but
ectopic expression of L-plastin has been reported in epithelial
malignancies including colon and breast cancers (Lin et al.,
1993). This appears to be critical in some tumors for
enhancing migration and invasion (Foran et al., 2006).
Aberrant expression of PLS3 mRNA was first identified in a
complementary DNA (cDNA) array–based study of peripheral
blood mononuclear cells from 48 SS patients (Kari et al.,
2003) and was proposed as a potential diagnostic biomarker.
Similar findings were reported by a representational difference
analysis study of mRNA derived from CD4þ /CD7-enriched
tumor cells from nine SS patients, which demonstrated
high levels of PLS3 mRNA expression in Se´zary cells and con-
firmed PLS3 protein expression by western blot analysis in
one patient (Su et al., 2003). Subsequent studies including
our own have identified that high levels of PLS3 mRNA
expression is a common feature of Se´zary cells (van Doorn
et al., 2004; Nebozhyn et al., 2006; Tiemessen et al., 2006;
Booken et al., 2008; Capriotti et al., 2008; Tang et al., 2010).
However, the mechanism by which aberrant expression of
PLS3 occurs in SS has not yet been determined. A key
potential mechanism that may contribute to the dysregulation
of PLS3 expression in SS is promoter methylation, as the PLS3
gene harbors a 1,585 bp CpG island (CGI), which may be
differentially methylated in Se´zary cells compared with
healthy T cells.
As PLS3 is not normally expressed by any cell of hema-
topoietic origin, it has potential as a Se´zary cell biomarker and
as a tool to evaluate the utility of other proposed markers for
the identification of SS tumor cells. Here we assess the extent
of PLS3 expression in CTCL and undertake a detailed
investigation of potential regulatory mechanisms. We further
show that an antibody against PLS3 can be used to identify a
subset of malignant circulating cells in SS and characterize in
detail the immunophenotype of this subset of malignant cells.
RESULTS
PLS3 is expressed in the majority of SS patients
To establish the prevalence of PLS3 in our patient cohort, the
expression of PLS3 mRNA was determined in CD4þ
peripheral blood lymphocytes (PBLs) by quantitative reverse
transcriptase–PCR (qPCR). qPCR detected a minimal amount
of PLS3 mRNA in 11 healthy controls representing one
thousandth of the amount of cyclophilin mRNA present. A
threshold for positive detection of PLS3 mRNA was set at one
hundredth of the amount of cyclophilin mRNA, using this
definition 60% (21/35) of SS patients expressed PLS3. A group
of 18 MF patients, 8 of whom had advanced-stage disease
(Stage IV) with no morphological evidence of Se´zary cells but
with a T-cell clone identical to that observed in the skin
(Stage B0b) and 10 of whom had skin-restricted disease (Stage
IB–III B0a) were also examined. Of the eight MF patients
with peripheral blood involvement, three expressed PLS3
(38%), whereas all those with skin-restricted disease were
PLS3 negative. Comparison of average PLS3 mRNA expres-
sion among the three groups demonstrated a significant
increase in PLS3 expression in SS patients compared with
healthy controls (Po0.05; Figure 1). The expression of PLS3
was also compared with measures of tumor burden such as
total lymphocyte count, CD4þ count, and CD4/CD8 ratio,
and demonstrated only a weak correlation (r¼0.33,
P¼0.008) with the percentage of CD4þ T cells.
The absence of coding or promoter mutations in the PLS3 gene
To address whether mutational events may be responsible for
aberrant PLS3 expression, PBL mRNA from six SS patients
was sequenced using primer sets that covered the entire
coding sequence and 953bp of the 1,111 bp 30-untranslated
region. No mutations were detected within the PLS3 coding
sequence and 30-untranslated region of the six patients
examined. A C/G polymorphism was observed in exon
1,390 bp upstream of the translational start site in two
patients. Further investigation revealed this site to be a
known single-nucleotide polymorphism, rs757124. As PLS3
mRNA was found with the C variant in four patients and
the G variant in two patients, we conclude that this
single-nucleotide polymorphism is not influencing the
expression of PLS3.
The promoter region of 12 SS patients was also sequenced
to establish whether other polymorphisms might be asso-
ciated with aberrant PLS3 expression. This cohort included
three SS patients not expressing PLS3 mRNA, eight SS patients
expressing PLS3, and one MF patient expressing PLS3. The
only polymorphisms detected within the region 1,845 bp
upstream of the transcriptional start site corresponded to
known single-nucleotide polymorphisms in this region
(Table 1). Although a much larger cohort is required to
conclusively test for an association between genotype and
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Figure 1. T-plastin (PLS3) mRNA is aberrantly expressed in CD4þ
lymphocytes from Se´zary syndrome (SS) patients. Quantitative reverse
transcriptase–PCR (qPCR) was used to assess the expression of PLS3 mRNA
in CD4þ lymphocytes from 11 healthy controls, 18 mycosis fungoides
(MF) patients, and 35 SS patients. The housekeeping gene Cyclophilin was
used as a normalization control. A significant difference between healthy
and SS patient expression was demonstrated by one-way analysis of variance
(ANOVA).
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Site-specific hypomethylation may contribute to aberrant PLS3
expression
Although Lin et al. (1999) found that the PLS3 CGI was
unmethylated in primary lymphocytes, the assay used only
investigated those CpG sites that were within the restriction
site of EagI, NruI, and PvuI. Therefore, we used direct
sequencing of bisulfite-converted DNA to examine the
methylation of the entire PLS3 CGI. The majority of the
CGI was observed to be unmethylated in healthy controls;
however, one small region containing CpG dinucleotides
95–99 was found to contain methylation in four healthy
lymphocyte samples but not in keratinocytes, which express
PLS3 (Figure 2a).
To investigate this region further, a pyrosequencing assay
was designed and used to quantify methylation in PBL samples
taken from 24 healthy controls and 36 SS patients. Healthy
PBLs were found to contain an average of 32% methylation of
CpG dinucleotides 95–99, which was significantly greater than
the 21% methylation observed in PLS3þ patient samples
(Po0.05). An average methylation level of 46% was detected
in PLS3 samples, which was not significantly different from
the healthy PBL samples (Figure 2b).
Development of an antibody against PLS3
We tested the two commercially available PLS3 antibodies by
western blotting and observed a lack of specificity and
sensitivity. Therefore, a polyclonal antibody was raised
against a PLS3 antigen and specificity was demonstrated by
western blotting (Figure 3a). Expression status of PLS3 protein
in SS PBLs was broadly consistent with the expression status
of PLS3 mRNA. Expression of PLS3 protein was demonstrated
in 8/11 SS samples shown to express PLS3 mRNA by qPCR,
whereas 2/3 SS samples with PLS3 mRNA levels below the
threshold showed no PLS3 protein expression. In the one SS
sample where PLS3 was detected at the protein level but not
the mRNA level, the quantity of PLS3 mRNA was just below
the threshold for PLS3 expression. Immunostaining of PBLs
from one PLS3-positive SS patient demonstrated PLS3 protein
expression in a proportion of lymphocytes and suggested that
the PLS3 protein is localized in the cytoplasm (Figure 1b).
PLS3þ cells are CD3þCD4þ and CD26 and heterogeneous
for other markers
Multiparameter flow cytometry was used to examine the
correlation of PLS3 expression with other immunophenotypic
markers including CD3, CD4, CD45RO, CD7, CD26,
CD25, and CD158k. PLS3þ cells were demonstrated in 11
of 16 SS samples by flow cytometry, and in all cases the
PLS3þ population also expressed CD3 and CD4 (Figure 4).
In those samples expressing PLS3, the PLS3þ cells com-
prised between 3 and 76% of the CD4þ PBLs (data not
shown).
Next, we examined the distribution of various phenotypic
markers within the PLS3þ and PLS3 populations (Figure 5).
Notably, in all 11 samples the CD4þ PLS3þ population
showed almost complete loss of CD26, whereas the corre-
sponding CD4þ PLS3 subsets expressed a significantly
greater proportion of CD26 (P¼0.0006), suggesting that loss
of CD26 is associated with gain of PLS3. However, no other
significant association was found between any of the other
differentiation markers and PLS3 status. Notably, a wide range
of CD45RO expression was observed, with four patients
demonstrating a significantly lower proportion (Po0.05) and
three patients showing a significantly greater proportion
(Po0.05) of CD45ROþ in the CD4þ subset than the healthy
control average of 47% (Figure 5). Although the distribution of
expression between PLS3 and PLS3þ subsets is variable, in
three patients showing significant reduction of CD45RO
expression, the PLS3 expression was confined to the
CD45RO population.
PLS3 expression is enriched in cells with the tumor-specific TCR
gene rearrangement
To assess whether PLS3 expression is heterogeneous in tumor
cells from individual patients, we used FACS to isolate
PLS3þ and PLS3 cell populations from one well-char-
acterized SS patient (R164). These cell populations were
analyzed for the presence of the patient-specific clonal TCR-b
gene rearrangement using a qPCR assay. The PLS3þ
population contained 84% (confidence interval 69–99%
Po0.05) cells with the tumor-specific clonal TCR-b gene
rearrangement, whereas the PLS3 population contained
28% (confidence interval 14–43% Po0.05) cells with the
tumor-specific clonal TCR-b gene rearrangement.
PLS3-positive cells show hypomethylation of CpG sites 95–99
DNA from the PLS3 and PLS3þ populations was also
analyzed for the methylation status of the PLS3 CGI at sites
95–99. In the pre-sort sample, DNA methylation across these
sites was 16%, whereas after sorting DNA from the PLS3þ
subset, which represented 79% of the pre-sort sample, was
found to be 10% methylated and DNA from the PLS3 subset
was 43% methylated.
Table 1. Genotypes of the three SNPs within the
T-plastin (PLS3) upstream region
Sample PLS3 expression rs3813931 rs1557770 rs757124
R67 + C/C T/T G/G
R73  C/C T/G G/C
R82 + ND G/G C/C
R83 + C/C T/T G/G
R84 + C/C T/T G/G
R85 + C/C T/T G/G
R89 + C/C T/T G/G
R118 (MF) + C/C T/T G/G
R122  T/T T /T C/C
R125 + C/C T/G G/C
R126  C/C T/T C/C
R133 + C/C T/T G/G
Abbreviations: MF, mycosis fungoides; ND, not determined; SNP, single-
nucleotide polymorphism.
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DISCUSSION
We have shown that aberrant expression of PLS3 is observed
in 60% of SS patients and 38% of MF patients with peripheral
blood involvement (stage B0b). No mutations were found in
the coding or regulatory regions of the PLS3 gene to account
for aberrant PLS3 expression in CTCL. Consistent with other
studies, no evidence of DNA methylation was found across
the bulk of the CGI (Lin et al., 1999; Oprea et al., 2008);
however, in a region that has not previously been investi-
gated, methylation was found in healthy lymphocytes but not
in keratinocytes, which correlates with PLS3 expression. In
contrast, this region was hypomethylated in lymphocytes
from PLS3þ SS patients. Furthermore, sorting of the PLS3þ
and PLS3 populations demonstrated that hypomethylation
was restricted to the PLS3þ population. These observations
strongly suggest that methylation of this region may
contribute to the silencing of PLS3 expression in healthy
lymphocytes and that loss of methylation may lead to
aberrant PLS3 expression in Se`zary cells. Further longitudinal
studies are now required to address whether therapies that
reduce tumor burden are associated with the reversal of the
observed hypomethylation.
We have previously demonstrated that Se´zary cells
are present within CD4þCD26þ , CD4þCD26, CD4þ
CD25, and CD4þCD25þ populations by quantifying
PLS3 mRNA within sorted cell subsets (Jones et al., 2010;
Tiemessen et al., 2006). In this study, we further explored the
correlation between T-cell differentiation marker expression
and PLS3 expression using an antibody specific for PLS3. In
all samples, PLS3 expression was observed to be restricted to
CD3þCD4þ T cells. We found that loss of CD26 was
significantly associated with the PLS3þ subpopulation,
whereas loss of CD7 and gain of CD158k were not. We also
observed that tumor cells were not exclusively confined to
the CD45ROþ population as widely reported (Willemze
et al., 1997). Indeed, in three samples with significant loss of
CD45RO, we were able to confirm that PLS3 expression was
confined to the CD45RO population. Similar results have
been reported recently, showing heterogeneity in CTCL
tumor cells in both CD45RO and CD45RA expression
(Campbell et al., 2010). The study by Campbell et al.
also identified significant differences in the expression
of cell differentiation markers and addressins in SS and MF
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Figure 2. CpG dinucleotides 95–99 are partially methylated in healthy lymphocytes, unmethylated in healthy keratinocytes, and show reduced
methylation in lymphocytes from Se´zary syndrome (SS) patients expressing T-plastin (PLS3). (a) Bisulfite-converted DNA from four healthy lymphocyte
samples and one healthy keratinocyte sample were sequenced to assess DNA methylation across the PLS3 CpG island (CGI). The section shown covers
CpG dinucleotides 95–99. The bisulfite-converted reference sequence shows potentially methylated cytosine residues (N) and the resultant Cþ T mixed
base (Y) highlighted in gray. (b) Pyrosequencing of bisulfite-converted DNA was used to measure methylation of CpG dinucleotides 95–99 in lymphocytes
from 24 healthy controls, and in tumor cells from 12 PLS3-negative (PLS3) and 24 PLS3-positive (PLS3þ ) SS patients. The median of each group is
represented by a horizontal line. A significant difference in methylation was demonstrated between healthy and PLS3þ groups by one-way analysis of
variance (ANOVA).
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compared with MF patients with skin-restricted disease.
Circulating tumor cells from leukemic patients were found
to express high levels of the lymph node–homing receptors
CCR7/L-selection and CD27, a phenotype consistent with
central memory T cells. MF tumor cells derived from lesional
skin lacked expression of the lymph node–homing markers
but expressed high levels of the skin-homing receptors CCR4
and CLA, a phenotype in keeping with skin-resident effector
memory T cells. Thus, it was proposed that SS and MF arise
from distinct functional T-cell subsets. As we did not include
such markers, our data do not address the functional T-cell
subset origin of CTCL tumor cells. However, the PLS3
antibody described may facilitate future validation of the
model proposed by Campbell et al. by using PLS3 expression
to identify CTCL tumor cells in effector versus central
memory T-cell populations, although heterogeneity in PLS3
expression within tumor cell populations may confound data
interpretation.
The wide range of proportions of PLS3þ cells observed
suggests that PLS3 expression is confined to a substantial
subset of tumor cells rather than the whole population. This
hypothesis is further supported by the detection of tumor cells
within the PLS3-negative population in one patient. This
effectively precludes the use of PLS3 sorting to isolate tumor
cells in SS patients expressing PLS3.
Although loss of CD7 and CD26 and gain of CD158k have
been proposed as diagnostic tools, it is not established
whether any of these markers can be used to quantify tumor
burden accurately. Our observations of phenotypic hetero-
geneity within the tumor population are supported by a
previous study, which determined that tumor cells are not
restricted to CD7 or CD26 subpopulations (Steinhoff
et al., 2009). This supports our conclusion that cell sorting
based upon these phenotypic markers is likely to identify only
a subset of tumor cells, although still potentially including
reactive cells. Therefore, isolation of the CD4þ subset still
provides the most reliable approach for the enrichment of the
tumor population in SS.
To quantify tumor cells within sorted cell subsets, we have
developed a patient-specific real-time TCR assay based upon
those used in acute lymphoblastic leukemia (Bruggemann
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Figure 3. A newly generated antibody is specific for the detection of
T-plastin (PLS3) protein. (a) Western blot analysis to determine PLS3
expression in primary keratinocytes, and lymphocyte samples from one
healthy control, 6 Se´zary syndrome (SS) patients shown to express PLS3
mRNA (R83, R63, R55, R58, R72, R85), and one SS patient who did not
express PLS3 mRNA (R73). PLS3-specific bands are at the expected size of
70 kDa. b-Actin (40 kDa) is included as a loading control. (b) Immunostaining
to detect PLS3 expression. Healthy CD4þ lymphocytes and SS patient
lymphocytes (R61) were cytospun onto slides, fixed in 1% paraformaldehyde,
permeabilized with ice-cold methanol, and then immunostained using the
PLS3-specific antibody or a rabbit polyclonal isotype control. Goat anti-rabbit
Alexa Fluor 488 (green) was used to visualize the staining, and nuclei were































Figure 4. T-plastin (PLS3)-positive cells are CD3þCD4þ . Lymphocytes
were stained with fluorescent antibodies against CD3, CD4, CD45RO, CD25,
CD26, CD7, CD158k, and PLS3, and then examined by flow cytometry.
Viable lymphocytes were gated into PLS3 and PLS3þ populations to allow
examination of CD3 and CD4 scatterplots. The example shown is taken from
Se´zary syndrome (SS) patient sample R164.
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chose to utilize a genetic assay rather than Vb antibodies to
enhance the specificity of detection and to avoid excluding
cells where cell surface TCR was not expressed. Patient-
specific real-time TCR copy number assays have the potential
for future use in quantifying tumor burden, allowing detailed
monitoring of response to therapies.
PLS3 and L-plastin are closely related actin-bundling
proteins, which normally demonstrate tissue-specific ex-
pression (Lin et al., 1993). However, aberrant L-plastin
expression has been demonstrated in a wide range of
epithelial malignancies (Lin et al., 1993) and shown to
induce proliferation and invasion in colon cancer cells
(Foran et al., 2006). In healthy tissue, L-plastin becomes
phosphorylated upon leukocyte activation (Wabnitz et al.,
2007) and leukocytes deficient for L-plastin are incapable of
killing pathogens despite showing normal migration, adhe-
sion, spreading, and phagocytosis (Chen et al., 2003). PLS3
has been proposed to have a role in DNA damage repair
(Sasaki et al., 2002; Ikeda et al., 2005) in healthy tissue
and is overexpressed in cisplatin-resistant (Hisano et al.,
1996) and UV-resistant (Higuchi et al., 1998) cells. Given
the importance of actin cytoskeletal dynamics in the
formation of the immunological synapse and the dysregula-
tion of T-cell signaling observed in CTCL, aberrantly
expressed PLS3 may interfere with the assembly of the
immunological synapse. Further investigation is necessary
to determine the functional role of aberrant PLS3 expression
in CTCL.
In conclusion, we have determined the prevalence of PLS3
expression in a large cohort of SS patients and developed an
antibody specific for PLS3, which should provide a valuable
tool for further studies into the functional role of PLS3. We
have demonstrated that hypomethylation of CpG dinucleo-
tides 95–99 in the PLS3 CGI is a likely mechanism
responsible for aberrant expression of PLS3 in Se´zary cells.
Longitudinal studies are now required to assess the prognostic
relevance of aberrant PLS3 expression in CTCL. We
further conclude that the expression of T-cell differentiation
markers in SS patients is heterogeneous and that CD4
expression remains the most reliable approach for enrich-
ment of tumor cells.
MATERIALS AND METHODS
Patient material
Patient lymphocytes were obtained from a nationally approved
research tissue bank (07/H10712/106) in accordance with the
Declaration of Helsinki Principles of 1975, as revised in 1983.
Lymphocytes were isolated using Lymphoprep (Axis-Shield, Kim-
bolton, UK) gradient centrifugation, whereas CD4þ lymphocytes
were obtained by incubating blood with RosetteSep CD4þ T-cell
enrichment cocktail (Stem Cell Technologies, London, UK) before
Lymhoprep gradient centrifugation. Diagnosis was made using the
WHO-EORTC diagnostic criteria for CTCL (Willemze et al., 2005).
All SS patients had an identical T-cell clone detected in lesional skin
and peripheral blood as demonstrated by TCR gene rearrangement
studies using BIOMED-2 primer sets (van Krieken et al., 2007).
Quantitative RT-PCR
RNA was isolated from CD4þ lymphocytes using the RNeasy mini
kit (Qiagen, Crawley, UK), followed by conversion into randomly
primed cDNA using the high-capacity cDNA archive kit (Applied
Biosystems, Warrington, UK). Quantitative RT-PCR was performed
on an ABI Prism 7000 (Applied Biosystems) using optimized TaqMan
probe/primer sets for PLS3 (Hs00192406_m1) and the endogenous
control Cyclophilin A (Hs99999904_m1).
Sequencing
DNA was isolated using standard procedures; cDNA was generated
as described above; bisulfite conversion was performed using the
Epitect bisulfite kit (Qiagen). Primer sequences and cycling condi-
tions are available on request. PCR products were sequenced by
Geneservice (London, UK) using the original PCR primers and
additional sequencing primers. Data were examined using Geneous
(Drummond et al., 2011) with a 25% peak height similarity cutoff to
detect potential mutations.
Pyrosequencing
Pyrosequencing was performed as described in Jones et al. (2010)
using the following primers: PLS39599_F-50-TGGAGTGGGGGT
TAATGGTAT-30, PLS39599_R-50-CCTCCCAATCCCTCTTAACAAA-
30 and sequencing primers PLS39599_SF-50-TTAAGTGGGTTGGA
GAGT-30, PLS39599_SR-50-AATCCCTCTTAACAAACC-30.
Antibody generation
Antibody production was performed by Cambridge Research

















































































Figure 5. T-cell differentiation marker expression is heterogeneous between
PLS3þ and PLS3 subsets. Lymphocytes were stained with fluorescent
antibodies against CD3, CD4, CD45RO, CD25, CD26, CD7, CD158k, and
PLS3, and then examined by flow cytometry. Viable cells were gated into
CD4þ PLS3S3 and CD4þ PLS3þ populations, and then the percentage of
positive cells was quantified for every other differentiation marker (CD45RO,
CD7, CD26, CD25, and CD158k) in each subset.
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Ac-MATTQISKDELDELKC-amide. Antisera were subjected to affinity
purification on thiopropyl sepharose 6B derivatized with the antigen
followed by elution using Glycine.
Western blotting
Western blotting was carried out using standard procedures.
Commercial antibodies against PLS3 used were ab45769 (AbCam,
Cambridge, UK) and sc-16655-R (Santa Cruz Biotechnology, Santa
Cruz, CA). Anti-b-actin (AbCam) was used as a loading control.
Flow cytometry
Lymphocytes were stained with LIVE DEAD Fixable Aqua dye (Life
Technologies, Paisley, UK) before incubation with APC-aCD26
(Miltenyi Biotech, Bisley, UK) and APC-Cy7-aCD158k (gift from
Dr Bagot conjugated using Innova Lightening-Link kit, Innova
Bioscience, Cambridge, UK) or appropriate isotype controls.
Following fixation and permeabilization, cells were incubated with
PE-Cy7-aCD3 (eBioscience, Hatfield, UK), PE-TxR-aCD4 (Caltag-
Medsystems, Little Balmer, UK), PacificBlue-aCD45RO (Biolegend,
Cambridge, UK), PE-Cy5-aCD7 (eBioscience), PE-aCD25 (eBioscience),
and DyLight488-aPLS3 (in-house antibody conjugated using Pierce
amine-reactive DyLight dye kit, Thermo Fisher Scientific, Rockford,
IL), or appropriate isotype controls. Flow cytometry acquisition and
sorting was performed on a FACSAria II (BD Biosciences, Oxford,
UK), and data were analyzed using the FlowJo software (Tree Star,
Ashland, OR).
Patient clone–specific qPCR assay
PCR/SSCP with the BIOMED-2 TCR-b primers was performed as
described in Fraser-Andrews et al. (2001) using the diagnostic
sample from SS patient R164. Clonal bands were sequenced
(Geneservice) using multiplexed forward or reverse BIOMED-2
primers. A rearrangement-specific forward primer was designed to
overlap V, D, and N regions. J region–specific reverse primer and
probe were synthesized according to published sequences. Quanti-
tative PCR was performed on an ABI 7000, and the assay was
validated using the diagnostic sample as a positive control and
pooled healthy lymphocyte DNA as a negative control. Sensitivity
was tested and a standard curve generated by spiking a synthetic
positive control into pooled healthy lymphocyte DNA. Patient-
specific Ct values were normalized against the Ct values from two
diploid genomic control regions (SDC4 and BCMA) to calculate the
proportion of tumor cells present in each cell subset.
Statistics
Comparison between two groups was made using Student’s t-test,
whereas comparisons among three groups were made by analysis of
variance. All statistical tests were performed using the R statistical
software package (http://www.r-project.org/).
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